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Abstract: It has been demonstrated that 1,25-dihydroxyvitamin D3 (1,25D) and  
some of its analogues have antitumor activity. 1,25D labeled with deuterium 
(26,26,26,27,27,27-hexadeuterated 1,25-dihydroxyvitamin D3, or 1,25D-d6) is commonly 
used as internal standard for 1,25D liquid chromatography-mass spectrometry (LC-MS) 
quantification. In the present study using human breast cancer cell lines, the biological 
activity of 1,25D-d6 administered alone and in combination with two commonly used 
antineoplastic agents, 5-fluorouracil and etoposide, was evaluated. Using an MTT assay, 
flow cytometry, and western blots, our data demonstrated that 1,25D-d6 has effects similar 
to the natural hormone on cell proliferation, cell cycle, and apoptosis. Furthermore, the 
combination of 1,25D-d6 and etoposide enhances the antitumoral effects of both 
compounds. Interestingly, the antitumoral effect is higher in the more aggressive  
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MDA-MB-231 breast cancer cell line. Our data indicate that 1,25D-d6 administered alone 
or in combination with chemotherapy could be a good experimental method for accurately 
quantifying active 1,25D levels in cultures or in biological fluids, on both in vitro breast 
cancer cell lines and in vivo animal experimental models.  
Keywords: 1,25-dihydroxyvitamin D3; 26,26,26,27,27,27-hexadeuterated 1,25-
dihydroxyvitamin D3; vitamin D; deuterated vitamin D; chemotheraphy; breast cancer 
 
1. Introduction 
In addition to its well known role in calcium homeostasis, numerous studies have demonstrated that 
1,25-dihydroxyvitamin D3 (1,25D) and its analogues affects other physiological or pathological 
processes, such as regulation of the proliferation and differentiation of various cell types. This has led 
to the study of its properties in several processes such as cancer [1–4]. In breast cancer 1,25D and 
some of its analogues inhibit cycle progression in MCF-7 human breast adenocarcinoma cells by 
arresting them in the G0/G1 phase [5,6]. Furthermore, this hormone also induces apoptosis, leading to 
morphological and biochemical effects such as cell shrinkage, chromatin condensation and DNA 
fragmentation. In turn, this inhibits tumor cell growth and contributes to tumor suppression [1,7,8]. 
Most of the above mentioned 1,25D-induced changes in gene expression and other parameters have 
been characterized by Muñoz et al. in several mammary tumor cell lines [9]. They showed that in 
human breast cancer cells with similar levels of vitamin D receptor (VDR) expression 1,25D treatment 
induces profound changes in phenotype (i.e., morphology, cytoarchitecture, size), proliferation, 
sensitivity to apoptotic stimuli, adhesiveness, migration, invasion, and the expression of marker genes 
associated with the inhibition of myoepithelial characteristics and with decreased malignancy. All of 
this may contribute to the vitamin’s protective action against neoplasia.  
1,25D and its analogues can also enhance, either synergistically or additively, the antitumor 
properties of several antineoplastic agents [10]. These properties have been demonstrated specifically 
in breast cancer cells by combining 1,25D with DNA-damaging agents (i.e., cisplatin and  
doxorubicin) [11,12], microtubule-disrupting agents (i.e., paclitaxel) [13], topoisomerase inhibitors 
(i.e., etoposide) [14] and with antimetabolites (i.e., 5-fluorouracil) [14].  
However, the dosage of 1,25D and analogues is a critical factor. Concern over possible side-effects 
such as hypercalcemia [10,15,16] may have led certain clinical studies to use low dosages that 
produced disappointing results [17–22]. Therefore, the ability to determinate its levels in patients may 
play an important role in treatment outcome. Deuterated forms of vitamin D are commonly  
used as internal standards for plasma quantifications by liquid chromatography-mass spectrometry  
(LC-MS) [23,24]. Thus, administration of 1,25D-d6 or a mixture of 1,25D-d6 and non-labeled 1,25D 
could allow accurately quantifying its concentration and bio-availability in an experimental  
model. One of these deuterated analogs of vitamin D is the 26,26,26,27,27,27-hexadeuterated  
1,25-dihydroxyvitamin D3 (1,25D-d6) (Figure 1A,B).  
To compare the effects of 1,25D and its deuterated form (1,25D-d6) on human breast cancer cells, 
these compounds were administered alone and in combination with two antineoplastic agents,  
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5-fluorouracil and etoposide, and then citotoxicity, cell cycle, apoptosis, and three-dimensional cell 
growth was evaluated. 
Figure 1. Structures of (A) 1,25-dihydroxyvitamin D3 (1,25D) and (B) its 
26,26,26,27,27,27-hexadeuterated analogue (1,25-dihydroxyvitamin D3-d6; 1,25D-d6). 
 
2. Results and Discussion 
To evaluate cell viability after 1,25D, 1,25D-d6, 5-fluorouracil, and etoposide administration, the 
human breast cancer lines were treated as described in the Experimental section, followed by an MTT 
assay at 48 h. We found that 1,25D-d6 produced effects similar to the natural hormone (1,25D), 
inducing significantly decreased cell viability in all cell lines, in relation to control cells (p = 0.001 in 
MCF-7 cells, p = 0.0007 in SKBR-3 cells, and p = 0.002 in MDA-MB-231 cells; Figure 2A–C). 
Combination of 1,25D-d6 with etoposide enhanced the effect on cell viability of each compound in all 
cell lines (1,25D-d6 + etoposide vs. 1,25D-d6 or etoposide, MCF-7 cells: p = 0.0002 and p = 0.002, 
respectively; SKBR-3 cells: p = 0.003 and p = 0.02, respectively; and MDA-MB-231 cells: p = 0.000006 
and p = 0.003, respectively).  
Figure 2. Cell viability in (A) MCF-7 cells; (B) SKBR-3 cells, and (C) MDA-MB-231 
cells 48 h after administration of placebo (control), 100 nM 1,25D, 100 Nm 1,25D-d6, 500 nM 
etoposide, 200 nM 5-fluorouracil, and the combination of these substances at the same 
doses. The values represent means ± SD from three independent determinations. a = p < 0.001 
vs. control cells; b = p < 0.01 vs. control cells; c = p < 0.05 vs. control cells; ns = not significant. 
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Figure 2. Cont. 
 
 
As shown in Figure 2C, decreased cell viability is greater in the more aggressive breast cancer 
MDA-MB-231 cell line than in MCF-7 or SKBR-3 cells. Administration of 5-fluorouracil plus either 
1,25D or 1,25D-d6 does not significantly reduce cell viability as compared with administration of  
each compound alone (Figure 2A–C). Decreased cell viability in the more aggressive cell line  
MDA-MB-231 after treatment with etoposide plus 1,25D or 1,25D-d6 could not be explained by 
vitamin D receptor (VDR) levels because these cells had lower VDR expression, compared with the 
other less aggressive MCF-7 and SKBR-3cell lines [25]. Lower VDR expression has also been 
demonstrated in invasive tumors as compared with normal tissue [26]. VDR levels are very important 
to inducing 1,25D-dependent anti-proliferative effects on breast cancer cells, but overexpression of 
VDR in MDA-MB-231 cells does not restores the sensitivity to the 1-hydroxyvitamin D5 analogue, 
as occurs in cells with high levels of VDR, suggesting that other factors are involved in  
1,25D-mediated inhibition of cell proliferation [27].  
Given that our results show that MDA-MB-231 cells are the most responsive to treatment with 
1,25D-d6 plus etoposide, we focused our next experiments on this cell line and this antineoplastic 
agent. The lower cell viability in MDA-MB-231 cells after treatment with 1,25D and 1,25D-d6  
plus etoposide could be explained by reduced cell proliferation or increased cell death. Therefore, we 
next investigated the effect of both hormones and etoposide on cell cycle and apoptosis. It is well 
known that etoposide is cell-cycle dependent and phase specific, inducing G2/M arrest and activation 
of p53 [28,29]. Our results corroborate this data. Figure 3A shows that administration of etoposide 
increased the G2/M phase in relation to control cells (p < 0.001). In addition, Western blot indicated 
that etoposide also increased cyclin A, cyclin B, and p53 expression (Figure 3B), suggesting that 
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decreased cell proliferation is due, at least in part, to alterations in cell cycle. Administration of 
etoposide plus 1,25D or 1,25D-d6 modifies neither G2/M phase of the cell cycle or p53, cyclin A, and 
cyclin B expression as compared with the administration of etoposide alone (Figure 3A,B). 
Figure 3. (A) Flow cytometry analysis of cell cycle in MDA-MB-231 cells after 48 h of 
treatment with placebo (control), 100 nM 1,25D, 100 nM 1,25D-d6, 500 nM etoposide, and 
1,25D or 100 nM 1,25D-d6 (100 nM) + etoposide (Eto, 500 nM). The values represent 
means ± SD from three independent determinations.*** = p < 0.001; (B) Western blot of 
p53, cyclin A, cyclin B, cyclin D and GAPDH (used as loading control) from protein 
extracts obtained from MDA-MB-231 cells treated as in (A). Numbers show the 
quantification of protein expression after normalization to GAPDH. A representative 
experiment is shown. 
 
Our next step was to evaluate cell death by flow cytometry. As shown in Figure 4A, administration 
of etoposide alone to the MDA-MB-231 cells induced an increased early (PI−/Ann+: 9.5 ± 3.5%) and 
late (PI+/Ann+: 25.8 ± 6.2%) apoptosis with respect to control cells (3.5 ± 2.8%, not significant, and 
14.0 ± 1.0%, p = 0.03, respectively). Administration of 1,25D plus etoposide (PI−/Ann+: 12.4 ± 2.5%, 
PI+/Ann+: 22.1 ± 2.7%) significantly enhances the effect on apoptosis with respect to administration 
of 1,25D (PI−/Ann+: 4 ± 2.6%, p = 0.02, PI+/Ann+: 14.1 ± 1.2%, p = 0.009, respectively), but not 
with respect to administration of etoposide alone. Administration of 1,25D-d6 plus etoposide  
enhances, but not significantly, early apoptosis with respect the administration of each compound 
(1,25D-d6 + etoposide versus 1,25D-d6 or etoposide, p = 0.081 and p = 0.3, respectively). We also used 
Western blot to analyse the expression levels of several proteins involved in the apoptosis pathway. 
Our data indicates that no significant changes were found in the anti-apoptotic Bcl-2 and the  
pro-apoptotic Bid proteins after administration either alone or in combination of etoposide, 1,25D, and 
1,25D-d6, in relation to control cells (Figure 4B). Administration of etoposide alone or combined either 
with 1,25D, or 1,25D-d6 increased the pro-apoptotic Bak protein. In addition, a visible increase in Bax, 
cleaved PARP, and active caspase-3 proteins after etoposide plus 1,25D, or 1,25D-d6 was observed, as 
compared with control cells and cells treated with 1,25D, 1,25D-d6, or etoposide alone (Figure 4B). 
Thus, our data seems to indicate a increased cell death when the MDA-MB-231 cells are treated with 
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etoposide plus 1,25D or 1,25D-d6. This cell death was clearly related to an increased early apoptosis, 
as shown by PI−/annexin V+ cells, and induction of pro-apoptotic markers, such as active caspase-3, 
cleaved PARP, Bax and Bak. Several reports have described the anti-tumor effects of 1,25D on cancer 
cells by regulating key mediators of apoptosis [10], suggesting that the most probable mechanisms  
are through the downregulation of the anti-apoptotic protein Bcl-2 [30], and disruption of 
mitochondrial function, which is associated with Bax translocation to mitochondria, cytochrome c 
release, and production of reactive oxygen species [31]. In addition, 1,25D-induced apoptosis via 
caspase-independent mechanisms has also been described [32]. Our results support the above 
mentioned caspase-dependent mechanism when either 1,25D or 1,25D-d6 are combined with etoposide. 
Figure 4. (A) Flow cytometry analysis using annexin-FICT and Propidium Iodide (PI) 
indicated increased apoptosis (PI−/Ann+ and PI+/Ann+) of MDA-MB-231 cells 48 h after 
administration of etoposide, and etoposide plus 1,25D, or 1,25D-d6 as compared to control 
cells. The values represent means ± SD from three independent determinations; (B) 
Western blot analyses of pro- (Bid, Bax, Bak, cleaved PARP, and active caspase-3) and 
anti- (Bcl-2) apoptotic proteins in MDA-MB-231 cells treated as in Figure 3A. Numbers 
show the quantification of protein expression after normalization to GAPDH. A 
representative experiment is shown. 
Groups PI−/Ann− PI−/Ann+ PI+/Ann+ PI+/Ann− 
Control 79 ± 1.9% 3.5 ± 2.8% 14.0 ± 1.0% 2.2 ± 0.6% 
1,25D 78.4 + 1.9% 4.0 ± 2.6% 14.1 ± 1.2% 1.7 ± 0.4% 
1,25D-d6 75.2 ± 2.4% 4.0 ± 2.7% 16.4 ± 1.2% 1.9 ± 0.1% 
Etoposide 56.8 ± 2.8% 9.5 ± 3.5% 25.8 ± 6.2% 5.6 ± 0.1% 
1,25D + Eto 56.0 ± 7.6% 12.4 ± 2.5% 22.1 ± 2.7% 6.3 ± 3.1% 
1,25D-d6 + Eto 56.0 ± 14.1% 16.1 ± 8.6% 21.0 ± 7.5% 4.2 ± 0.3% 
 
B
Bcl-2
Bid
Caspase 3
GAPDH
Bax
Bak
Parp
68     61    65     66     69     68
46     46    49     44     46     54
23     25    23     25     37     37
47     49    43     59     67     63
6      5      6     7       19     20
36     39    49     58     71     69
A 
Cancers 2014, 6                            
 
 
73 
We also explored three-dimensional growth of MDA-MB-231 cells. Figure 5 shows that treatment 
with etoposide produced a significant decrease (p = 0.0007) in sphere diameter compared with control 
cells, and this effect increased when etoposide was combined with 1,25D-d6 (p = 0.002).  
Figure 5. Three-dimensional growth of MDA-MB-231 cells 48 h after treatment with 
placebo (control), 100 nM 1,25D-d6, 500 nM etoposide, and 100 nM 1,25D-d6 plus 500 nM 
etoposide. The values represent means ± SD from three independent determinations.  
a = p< 0.05 vs. control; b = p < 0.001 vs. control; c = p < 0.01 vs. etoposide.  
 
Previous studies have reported that some deuterated vitamin D analogs have similar or lower effects 
than their non-deuterated forms on clonal growth and cell differentiation in several leukemia cell lines, 
in addition to stimulating intestinal calcium absorption and bone calcium mobilization [33]. However, 
other studies have demonstrated deuterated 1,25D to be more potent at lower concentrations than 
1,25D on growth plate cartilage [34]. A recent study demonstrated that, when deuterated, the gemini 
vitamin D analogues (derivatives of 1,25D with two chains emanating at C20) showed higher 
bioactivity, probably by stabilizing the ligand binding domain (LBD) of the VDR and by enhanced 
coactivator interactions [35]. Our data do not reveal significant differences in bioactivity between 
1,25D and 1,25D-d6 when combined with etoposide. It has been demonstrated that etoposide inhibits 
the ability of 1,25D to cause accumulation of 25-hydroxyvitamin D3 24-hydroxylase mRNA(CYP24), 
an enzyme that catabolizes this hormone, thus increasing the bioavailability of 1,25D [36]. Although 
we did not evaluate CYP24 mRNA levels, we found that etoposide in combination with 1,25D-d6 had 
similar effects to 1,25D plus etoposide on cell viability, cell proliferation, and apoptosis. Thus, it 
seems reasonable to assume that similar mechanisms are involved with 1,25D-d6, and to speculate that 
etoposide could also increase its bioavailability and providing it with similar biological activity, at 
least in the mammary tumor cell lines used in our experimental approach. 
In summary, our results seems to indicate that administration of etoposide (and perhaps other 
antineoplastic agents) plus 1,25D-d6, instead of the non-deuterated form, could be a better method for 
accurately quantifying its concentration in breast cancer cell lines or in animal experimental models  
in vivo.  
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3. Experimental Section  
3.1. Cell Culture and Drugs 
The human breast carcinoma cell lines MCF-7, SK-BR-3, and MDA-MB-231, obtained from the 
European Collection of Cell Cultures (Salisbury, Wilts, UK), were grown in 90 mm petri dishes in 
DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL 
streptomycin, and 2 mM L-glutamine in an air-CO2 (95:5) atmosphere at 37 °C. Confluent cells were 
washed twice with PBS and harvested by a brief incubation with trypsin-EDTA solution (Sigma-Aldrich, 
Madrid, Spain) in PBS. 1,25D and 1,25 D-d6 were provided by Profs. Antonio Mouriño and Miguel 
Maestro (University of Santiago de Compostela, Santiago de Compostela, Spain). 5-Fluorouracil and 
etoposide were obtained from Ferrer Farma (Barcelona, Spain) and Teva Genéricos Española, S.L. 
(Madrid, Spain). 5-Fluorouracil and etoposide were dissolved in PBS and used at 200 nM and  
500 nM, respectively.  
3.2. Treatments 
Cell lines were treated either with 1,25D or 1,25D-d6 at 100 nM. The two antineoplastic agents, 
etoposide and 5-fluorouracil were used at 500 nM and 200 nM, respectively. The same doses were 
used when combined with 1,25D or 1,25D-d6. 
3.3. MTT Metabolization 
Cell viability experiments were carried out using MTT assay. Cells (2.5 × 10
4
 cells/mL) were 
seeded in a volume of 0.5 mL into 24-well tissue culture plates. MCF-7, SKBR-3, and MDA-MB231 
cell lines were treated after 24 h as described above. The absorbance of the samples was recorded 48 h 
after treatment at 570 nm in a multiwell plate reader (LB 940 Mithras, Berthold Technologies, Bad 
Wildbad, Germany). Results were plotted for each cell line as the mean ± SD values of quadruplicates 
from at least two independent experiments. 
3.4. Cell Cycle and Apoptosis Assays  
Cell cycle and apoptosis assays were carried out by using a Guava flow cytometer (Millipore 
Corporation, Billerica, MA, USA). Briefly, 2 × 10
5
 cells/well were cultured in DMEN. Forty-eight 
hours later, cell were harvested, fixed with 70% cold ethanol for 30 min, washed with PBS, and 
incubated with ribonuclease (100 µg/mL), and propidium iodide (PI, 50 µg/mL) for 60 min in 
darkness, for cell cycle evaluation. Apoptosis analyses were performed using Annexin V (Ann)-FITC. 
Cells (2 × 10
5
) were harvested, washed twice with PBS, and resuspended in 1 × binding buffer (10 mM 
Hepes (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl2). 5 µL of FITC-Annexin V was added and 
incubated for 15 min at room temperature in darkness. Finally, 400 µL of 1 × binding buffer was added 
to each tube, and analyzed.  
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3.5. Western Blot Assays 
Western blotting of MDA-MB231 cells was performed as previously described [37]. Briefly, 50 µg 
of total protein was subjected to SDS–PAGE electrophoresis. Proteins were transferred to a 
nitrocellulose membrane, blocked, and immunolabeled overnight at 4 °C with a primary antibody, and 
then incubated with the appropriate secondary antibody. The signal was detected with the Pierce ECL 
Western blotting substrate (Thermo Scientific, Rockford, IL, USA) and visualized by putting the blot 
in contact with standard X-ray film following the manufacturer’s instructions. The following 
antibodies were used: anti-cleaved PARP, anti-Bcl-2, anti-Cyclin D, anti-p-53, and anti-GAPDH 
(Santa Cruz Biotechnology, CA, USA), anti-active Caspase-3, anti- Cyclin A, and anti-Cyclin B (BD 
Biosciences, San Diego, CA, USA), and anti-Bid, anti-Bax and anti-Bak (Cell Signaling Technology, 
Danvers, MA, USA). 
3.6. Three-Dimensional Cell Culture  
For 3D cell culture, 12 mm coverslips were coated with 60 µL of ice-cold Matrigel (BD 
Biosciences) and incubated at 37 °C for 20 min to allow the Matrigel to solidify. Cells were treated for 
5 min with 0.25% trypsin-EDTA solution (2.5 g/L of trypsin, 0.38 g/L of EDTA; Sigma, Madrid, 
Spain). A single cell suspension containing 5 × 10
3
 cells per 100 µL of culture medium, supplemented 
with 2% (vol/vol) of Matrigel, was carefully placed on the coverslips on top of the solidified Matrigel 
and incubated at 37 °C for 30 min. Coverslips were then placed in six-well plates with 500 µL of 
culture medium per well. After 10 days, cells were treated with 1,25D-d6 and etoposide alone or in 
combination for one week. Photographs of the 3D cultures were taken with a Nikon Eclipse Ti-S 
inverted microscope (Izasa, Barcelona, Spain) equipped with a ProgRes C3 camera and the ProgRess 
Capture Pro 2.7 software [38]. Quantification of the sphere diameters was made manually by tracing a 
straight line across the diameter of the sphere and scoring its value as arbitrary length units. 50 spheres 
were scored for each condition to calculate the mean.  
3.7. Statistical Analysis 
Each experiment was performed at least three times. Values are expressed as mean ± standard 
deviation. Means were compared using one-way ANOVA, with the Tukey’s test for post hoc 
comparisons. p values of less than 0.05 were considered statistically significant. The MATLAB 
R2011a Version7.1 software [39] was used for all calculations.  
4. Conclusions 
Our data indicates that 1,25D-d6 had similar bioactivity to the natural hormone 1,25D when 
combined with the antineoplastic drug, etoposide. Combined with 1,25D-d6, etoposide enhanced the 
antitumoral activity of each drug on cell viability in the breast cancer cell lines MCF-7, SKBR-3 and 
MDA-MB-231. Interestingly, the antitumor effect was higher in the more aggressive cell line  
MDA-MB-231. Our results support that 1,25D-d6 administered alone or in combination with 
chemotherapy could be a good experimental method for accurately quantifying its concentration in 
culture medium or biological fluids.  
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